Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Myrtle Y Gordon"'
This book is an impressive compilation of contributions on the hot topic of cardiac stem cell therapy from leading groups all over the world. In the assembly of chapters, a structured approach is adopted; starting from the clinician's perspective, al
Stem cells have generated considerable interest recently in the scientific, clinical, and public arenas. The third book in the Stem Cell Repair and Regeneration series offers contributions from numerous areas bridging medicine and the life sciences.S
Stem cell research is one of the leading “cutting edge” areas of life science research in the world today and is a topic of significant interest to a broad range of the medical and scientific community. This authoritative book provides reviews by
This second book in the Stem Cell Repair and Regeneration series provides a deeper exploration of the therapeutic potential of undifferentiated human stem cells.Regenerative medicine is an extremely fast-moving field which is evolving from the initia
Autor:
Steen Lindkaer Jensen, J. Davis, Stephen Marley, Soma Banerjee, Joanna Nicholls, M. Hamady, Abdul Shlebak, Nagy A. Habib, Jeremy Chataway, Myrtle Y. Gordon, Deborah A Williamson, Paul Bentley
Publikováno v:
Stem Cells Translational Medicine. 3:1322-1330
Treatment with CD34+ hematopoietic stem/progenitor cells has been shown to improve functional recovery in nonhuman models of ischemic stroke via promotion of angiogenesis and neurogenesis. We aimed to determine the safety and feasibility of treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2723634beb7c2ef81a6dc30638240e5a
https://doi.org/10.5966/sctm.2013-0178
https://doi.org/10.5966/sctm.2013-0178
Autor:
Stefan D. Anker, Darlington O. Okonko, Myrtle Y. Gordon, Philip A. Poole-Wilson, Stephen B. Marley
Publikováno v:
International Journal of Cardiology. 166:664-671
Anaemia is a prevalent and adverse comorbidity in chronic heart failure (CHF) but its origins are frequently elusive. Diffuse inflammation is also prominent in CHF and a potent inhibitor of erythrocyte production. We tested the hypothesis that unexpl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09bb727fbdf856f5c30c3c9d4f67973
https://doi.org/10.1016/j.ijcard.2011.11.081
https://doi.org/10.1016/j.ijcard.2011.11.081
Publikováno v:
Leukemia supplements. 1(Suppl 2)
Although chronic myeloid leukemia (CML) is now defined on the basis of the presence of the BCR-ABL1 fusion gene, which may or may not be the initial genetic event that triggers the inappropriate expansion of the myeloid cell mass, CML, similar to oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64dfefd0dfab7897ec587468008e0f78
https://pubmed.ncbi.nlm.nih.gov/27175247
https://pubmed.ncbi.nlm.nih.gov/27175247
Publikováno v:
Stem Cells and Development. 21:2565-2580
In the present study, we investigated how the symmetry/asymmetry of cell division in mitotic CD34(+) cells can be evaluated by determining the plane of cell division and the potential distribution of proteins between daughter cells. The orientation o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a24f01a661b9ab2ce771c98ce653abaa
https://doi.org/10.1089/scd.2011.0467
https://doi.org/10.1089/scd.2011.0467
Autor:
Amanda Jackson, Myrtle Y. Gordon, Georgios Nteliopoulos, Zacharoula Nikolakopoulou, Hetal Patel
Publikováno v:
British Journal of Haematology. 152:611-614
Multiprotein complex formation with p210(BCR-ABL1) is likely to play a major role in determining cellular abnormalities in chronic myeloid leukaemia (CML). Although many p210(BCR-ABL1) binding partners have been identified, it is likely that many hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35e87e832e9ed380dbe79089764d1dae
https://doi.org/10.1111/j.1365-2141.2010.08450.x
https://doi.org/10.1111/j.1365-2141.2010.08450.x
Publikováno v:
Age and Ageing. 40:7-13
Stroke is a leading cause of death and disability. Globally, 15 million people suffer a stroke each year, of whom more than 5 million die, and a further 5 million are left permanently disabled. Current treatment options offer modest benefits, and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77e3f3bfa15a0aa45b854208370879e4
https://doi.org/10.1093/ageing/afq133
https://doi.org/10.1093/ageing/afq133